Skip to main content

UBS Group AG

Position in LGND — Ligand Pharmaceuticals Inc

CIK 1610520 ZURICH, V8

Position in LGND

as of Mar 31, 2026 · filed May 5, 2026
Position Value
$20,879,395
-$6,170,282 QoQ
Shares Held
104,580
-26.9% QoQ
Ownership
0.522%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 94.33830560336585.ToString("F0")% Shared 0.ToString("F0")% None 5.6616943966341555.ToString("F0")%

Common Shares in LGND Over Time

Shares Held

Position Value (USD)

Derivatives in LGND

reported options exposure · as of Jun 30, 2021
CallValue
$736,562
CallShares
9,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

UBS Group AG holds $8,307,109,707 across 562 Biotechnology names. LGND ranks #69 (0.3% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in LGND

Export CSV
31 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $20,879,395 104,580
2025-12-31 $27,049,677 143,067
2025-09-30 $19,837,198 111,986
2025-06-30 $3,809,416 33,510
2025-03-31 $3,200,039 30,436
2024-12-31 $2,904,300 27,105
2024-09-30 $1,150,734 11,497
2024-06-30 $3,268,107 38,786
2024-03-31 $2,416,904 33,063
2023-12-31 $1,358,908 19,027
2023-09-30 $414,406 6,916
2023-06-30 $582,207 8,075
2023-03-31 $86,873 1,181
2022-12-31 $110,888 1,660
2022-09-30 $19,338 360
2022-06-30 $37,289 670
2022-03-31 $2,195,344 31,284
2021-12-31 $2,588,914 26,868
2021-09-30 $2,341,581 26,942
2021-06-30 $787,549 9,623
2021-06-30 $736,562 9,000
2021-03-31 $1,521,646 16,000
2021-03-31 $357,016 3,754
2021-03-31 $7,256,351 76,300
2020-12-31 $323,909 5,221
2020-12-31 $2,072,132 33,400
2020-09-30 $309,210 5,200
2020-09-30 $286,851 4,824
2020-06-30 $528,827 7,579
2020-03-31 $196,792 4,338
2020-03-31 $476,331 10,500